Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this survey is to examine the effect on quality of life (QOL) improvement and
convenience of switching to leuprorelin acetate 3 months depot 11.25 milligram (mg) injection
kit (Leuplin SR 11.25 mg injection kit) from a 4-week adjuvant therapy with a luteinizing
hormone-releasing hormone analog (LH-RHa) 1 month depot over 48 weeks in premenopausal breast
cancer participants in daily medical practice. Influence of condition of estrogen receptor
expression on the efficacy and safety of leuprorelin acetate SR 11.25 mg injection kit was
also evaluated.